Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Airbus Joins Air India A320 Altitude Drop Probe 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
US Judge Dismisses Gautam Adani Criminal Charges 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
ADNOC Gas Targets Up to $4B Profit in 2026 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Sanofi (NASDAQ:SNY), in partnership with Vietnam Vaccine JSC (VNVC), officially launched a state-of-the-art vaccine production facility in Vietnam, marking a major step in boosting the country’s pharmaceutical manufacturing capabilities. The new plant is designed to supply vaccines for both domestic distribution and global export, supporting broader public health goals across Asia and beyond.
The inauguration ceremony, held on Tuesday, was attended by French President Emmanuel Macron during his diplomatic visit to the Southeast Asian nation, underscoring the importance of international collaboration in advancing healthcare access.
Strategically located to serve Vietnam’s growing healthcare needs, the facility enhances local vaccine self-sufficiency while contributing to the global vaccine supply chain. It is part of Sanofi’s ongoing effort to expand its footprint in emerging markets and reinforce its role as a global vaccine leader.
The launch comes amid heightened global attention on vaccine access and preparedness following recent pandemics. By leveraging cutting-edge technology and Sanofi’s extensive vaccine expertise, the facility aims to strengthen Vietnam’s position as a regional hub for pharmaceutical innovation and production.
This initiative reflects Sanofi’s commitment to investing in sustainable healthcare infrastructure and VNVC’s mission to improve immunization access across Vietnam. The collaboration also aligns with government goals to attract high-quality foreign investment in biotechnology and life sciences.
With the new facility operational, Sanofi and VNVC are well-positioned to meet growing demand for essential vaccines, not only within Vietnam but across neighboring countries, contributing to improved regional health outcomes.
The opening of this manufacturing site marks a significant milestone in Vietnam’s healthcare development, offering long-term benefits in vaccine accessibility, economic growth, and international cooperation in the pharmaceutical sector.
